Wells Fargo analyst Tiago Fauth raised the firm’s price target on PTC Therapeutics (PTCT) to $93 from $73 and keeps an Overweight rating on the shares. The firm notes the PKU launch is off to a strong start, and without stocking this represents organic uptake. Wells thinks persistence, and degree of switching will be key. FDA meeting on votoplam could be a sleepy catalyst, the firm adds.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics price target raised to $68 from $46 at Barclays
- PTC Therapeutics price target raised to $75 from $50 at Citi
- PTC Therapeutics: Strong Market Position and Growth Potential Drive Buy Rating
- PTC Therapeutics: Balancing Sephience Success with DMD Challenges and Strategic Shifts
- PTC Therapeutics Reports Strong Q3 2025 Results